Bacterial meningitis is a major cause of morbidity and mortality in childhood. Antibiotic treatment recommendations are based on epidemiological and susceptibility data. The epidemiology of bacterialméningitis has changed in recent years, mainly owing to widespread use of different conjugate vaccines. The aim of this prospective national survey is to describe epidemiology of bacteria implicated in bacterial meningitis in children.
clinical signs of meningitis, associated with positive cerebrospinal fluid (CSF) culture and/or positive CSF antigen testing (Escherichia coli K1, N. meningitidis serogroups B, A, C, Y and W-135, group B streptococci, Hib, or S. pneumoniae), and/or positive CSF polymerase chain reaction (PCR), and/or positive blood culture with CSF pleocytosis (> 10 cells/µL).
purpura fulminans
None
children 0 day to 18 years with bacterial meningitis or purpura fulminans
Case-only
Prospective
Not listed
mortality
Number of death according to age and bacteria
treatment failures
Number of antibiotic treatment failures according to bacteria after the control of lumbar puncture
impact of vaccines
Number of vaccination failures according to age, number of doses and bacteria
Click on the lead sponsor to view all of their trials.
Association Clinique Thérapeutique Infantile du val de Marne
Lead sponsor
Pfizer
Collaborator
